This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -24.14% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 14.71% and 3.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Karyopharm Therapeutics (KPTI) Rating Upgrade to Buy
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 11.76% and 2.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Karyopharm Therapeutics (KPTI) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -26.47% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Karyopharm Therapeutics (KPTI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 96% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Karyopharm Therapeutics (KPTI) points to a 96.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 19.64% and 3.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aziyo Biologics, Inc. (AZYO) Soars 11.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Aziyo Biologics, Inc. (AZYO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 1.59% and 9.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 15.87% and 37.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm Therapeutics (KPTI) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 215% and 125.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Karyopharm (KPTI)
by Zacks Equity Research
Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Karyopharm's (KPTI) Eltanexor Gets Orphan Drug Tag for MDS
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Karyopharm's (KPTI) investigational candidate, eltanexor, for treating myelodysplastic syndromes.
Implied Volatility Surging for Karyopharm (KPTI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -1.47% and 45.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.